Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02179359 · ClinicalTrials.gov registry record · NA
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT02179359 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 38 participants.
The verdict
NCT02179359, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
Interventions
- DRUG Reduced Toxicity Ablative Regimen
- DRUG Reduced Intensity Preparative Regimen
- DRUG Myeloablative Preparative Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-09-02 |
| Est. Completion | 2024-11-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02179359
The ClinicalTrials.gov registry entry for NCT02179359 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Reduced Toxicity Ablative Regimen is the first listed.
NCT02179359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02179359 about?
NCT02179359 is a clinical study titled "Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies". This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
What is the current status of trial NCT02179359?
This trial is currently terminated. It is a NA study. The enrollment target is 38 participants. The study started on 2014-09-02. Estimated completion is 2024-11-21.
What interventions are being tested in trial NCT02179359?
The interventions under investigation include: Reduced Toxicity Ablative Regimen (DRUG), Reduced Intensity Preparative Regimen (DRUG), Myeloablative Preparative Regimen (DRUG).
Who is sponsoring clinical trial NCT02179359?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.